Envista Holdings Logo
US29415F1049
A2PN69
0HV.DE

Envista Holdings

Kurser indlæses...

Prognose

Analytikernes gennemsnitlige kursmål er 25,50 € (+14,35 %). Medianen er 24,49 € (+9,82 %).

Køb
  8
Behold
  11
Sælg
  1

Diskussioner i communityet

Der er endnu ingen diskussion om dette aktiv.

Start diskussion

  • Envista rises premarket after JPMorgan upgrade and price-target increase

    Envista shares rose about 2.3% premarket after JPMorgan upgraded the stock from “Neutral” to “Overweight” and raised the price target from $29 to $32. The bank cited improved operational execution and a valuation that lags recent fundamentals, and expects to set a mid‑term growth target slightly above the previous 2–4% range at the investor day on Sept. 17. Envista had already reported Q2 results that beat expectations on adjusted EPS and revenue and subsequently raised its full‑year forecast. » Mere på de.investing.com


  • Envista Holdings: CEO Paul Keel named chair of the board; executives receive special compensation

    Envista Holdings named President and CEO Paul Keel effective immediately as chair of the board; Scott Huennekens remains lead independent director. The board approved a salary increase for Keel from $1.1 million to $1.3 million and a one-time equity award worth $10 million ($5 million RSUs, $5 million PSUs with a four-year vesting period). CFO Eric Hammes received PSUs worth $1.5 million with the same performance conditions. The actions are based on an SEC filing; Envista recently reported Q2 results and revenue above expectations and raised its full-year outlook. » Mere på de.investing.com


  • Envista raises 2026 outlook after Q2 sales, margin and EPS beat

    Envista reported Q2 sales of $731 million, driven by 5% core revenue growth, with adjusted EBITDA up 28% and adjusted EPS of $0.41 (up 58%). Free cash flow was $105 million and the company repurchased about 2.4 million shares. Equipment and consumables led segment growth while Specialty Products saw strength from Spark clear aligners and implant investments. Management raised 2026 guidance to 3.5–4.5% core sales growth, 11–14% adjusted EBITDA growth and adjusted EPS of $1.50–$1.55, but warned China volume-based procurement could pressure pricing in H2. » Mere på finance.yahoo.com


  • Envista Holdings announces $300 million share buyback program and confirms outlook

    Envista Holdings reports Q1 revenue growth (+14.4% nominal; organic +9.5% before special items), adjusted EBITDA of $98.9 million (+25%) and adjusted earnings per share of $0.36. Operating cash flow and free cash flow were negative, driven by higher investments in plants in China and Finland. Management confirms the full-year outlook (organic growth 2–4%, adjusted EBITDA +7–13%) and launches a new $300 million repurchase program through the end of 2029. The stock is likely to trade sideways in the short term; the next price catalysts are expected from the quarterly results on August 5. » Mere på finanzen.net


  • Envista Holdings named a top Ariel Investments pick after strong Q1 momentum

    Ariel Investments lists Envista Holdings as a top stock to buy following a strong first quarter marked by 9.5% core revenue growth, 25% adjusted EBITDA growth and 50% EPS growth. Barclays reiterated an Overweight rating but trimmed its price target to $32 from $34. Envista reiterated full-year guidance with sales growth of 2–4%, adjusted EBITDA growth of 7–13% and adjusted diluted EPS guidance of $1.35–$1.45. » Mere på finance.yahoo.com

Virksomhedstal

I det seneste kvartal havde Envista Holdings en omsætning på 614,16 mio. € og et nettoresultat på 451,45 mio. €
(EUR) oktober 2026
YoY
Omsætning 614,16 mio. 7,29 %
Bruttofortjeneste 355,79 mio. 11,00 %
Nettoresultat 451,45 mio. 1.843,59 %
EBITDA 473,74 mio. 529,28 %

Fundamentale data

Nøgletal Værdi
Markedsværdi
3,58 mia. €
Antal aktier
160,35 mio.
Højeste/laveste i 52 uger
27,60 € - 17,03 €
Udbytte Nej
Beta
0,94
P/E (PE Ratio)
6,26
PEG (PEG Ratio)
0,00
K/I (PB Ratio)
1,28
P/S (PS Ratio)
1,37

Virksomhedsprofil

Envista Holdings Corporation og dets datterselskaber udvikler, sælger og markedsfører tandlægeprodukter i USA, Kina og internationalt. Virksomheden opererer i to segmenter, Specialty Products & Technologies og Equipment & Consumables. Virksomhedens segment Specialty Products & Technologies leverer tandimplantatsystemer, guidede kirurgiske systemer, biomaterialer samt præfabrikerede og specialfremstillede proteser til oralkirurger, protetikere og parodontologer under mærkerne Nobel Biocare, Alpha-Bio Tec, Implant Direct, Nobel Procera og Orascoptic; og brackets og tråde, rør og bånd, buetråde, gennemsigtige aligners, digitale ortodontiske behandlinger, retainere og andre ortodontiske laboratorieprodukter under mærkerne Damon, Insignia, AOA og Spark. Segmentet tilbyder også softwarepakker, herunder DTX Studio Implant til behandlingsplanlægning af tandimplantater; TX Studio Lab til behandlingsplanlægning af proteser; og DTX Studio Clinic til lagring og adgang til forskellige kliniske patientbilleder. Virksomhedens segment Equipment & Consumables leverer tandudstyr og forbrugsvarer, herunder digitale billeddannelsessystemer, sensorer, software og andre visualiserings- og forstørrelsessystemer; endodontiske systemer og tilhørende forbrugsvarer; restaureringsmaterialer, roterende bor, aftrykmaterialer, bondingmidler og cementer; samt infektionsforebyggende produkter. Segmentet tilbyder sine produkter under mærkerne Dexis, Gendex, i-CAT, Kerr, Metrex, Total Care, Pentron, Optibond, Harmonize, Sonicfill, Sybron Endo og CaviWipes til tandklinikker, klinikker og hospitaler. Envista Holdings Corporation blev stiftet i 2018 og har hovedkontor i Brea, Californien.

Navn
Envista Holdings
CEO
Paul A. Keel
Hjemsted Brea, ca
USA
Websted
Sektor
Sundhed
Branche
Sundhedsudstyr og -produkter
Børsnotering
18.09.2019
Medarbejdere 12.000

Tickersymboler

Børs Symbol
XETRA
0HV.DE
NYSE
NVST
Düsseldorf
0HV.DU
Frankfurt
0HV.F
München
0HV.MU
Toronto Stock Exchange
CLZ.V
Pnk
ICRD
🍪

Parqet  bruger cookies. Læs mere